Tumor burden monitoring with circulating tumor DNA in esophageal squamous cell carcinoma patients

Tumor burden monitoring with circulating tumor DNA in esophageal squamous cell carcinoma patients - Circulating tumor DNA monitoring in esophageal cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000038724

Enrollment

100

Registered

2019-11-30

Start date

2015-09-23

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

esophageal squamous cell carcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients aged 20 or older with ESCC who underwent esophageal cancer treatment including surgery, chemotherapy, and radiotherapy. 1. Patients must have given written an informed consent 2. Histologically confirmed ESCC 3. ESCC Patients treated by standard of care therapy followed by post-treatment surveillance

Exclusion criteria

Exclusion criteria: 1. Patients unable to undergo biopsy for initial tissue diagnosis 2. Patients who do not wish to pursue standard of care therapy 3. Patients with different diagnosis of malignancy

Design outcomes

Primary

Measure	Time frame
ctDNA dynamics and clinical relapse by conventional surveillance modalities are compared if ctDNA provides useful information on the early detection of relapse.	—

Secondary

Measure	Time frame
1. Association of ctDNA detection and tumor stage or tumor volume 2. ctDNA monitoring and accurate diagnosis of chemotherapy/chemoradiotherapy efficacy 3. ctDNA monitoring and disease-free confirmation 4. Pretreatment ctDNA detection and overall survival 5. Clearance of ctDNA and overall survival	—

Countries

Japan

Contacts

Public ContactTakeshi Iwaya

Iwate Medical University Hospital Department of Surgery

tiwaya@iwate-med.ac.jp0196137111

Outcome results